Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Zacks spotlights ORCL, NVO, LIN, NVEC and CPSH for their strategic growth plays, from AI cloud to medtech sensing and advanced materials.

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...